OrbiMed's Isaly: Biotech Slump 'Has Been Overdone'

OrbiMed's Isaly: Biotech Slump 'Has Been Overdone'

Assessment

Interactive Video

Business, Other

University

Hard

Created by

Quizizz Content

FREE Resource

The video discusses the biotech market slump, noting it was overdone and signs of recovery are visible. Valuation challenges are highlighted, especially for companies without profits. The focus shifts to breakthrough technologies and therapies, emphasizing their importance and rapid advancement. The video also covers trends in the IPO market, noting difficulties for nascent biotech companies but highlighting the potential for exciting technologies to secure funding.

Read more

2 questions

Show all answers

1.

OPEN ENDED QUESTION

3 mins • 1 pt

What factors are contributing to the slowdown in IPOs for biotech companies?

Evaluate responses using AI:

OFF

2.

OPEN ENDED QUESTION

3 mins • 1 pt

Which recent biotech companies are mentioned as being noteworthy?

Evaluate responses using AI:

OFF